<DOC>
	<DOCNO>NCT01846793</DOCNO>
	<brief_summary>This study design demonstrate safety efficacy second transrectal intraprostatic injection NX-1207 give subject Benign Prostatic Hyperplasia ( BPH ) previously receive injection NX-1207 early U.S. clinical trial NX-1207 .</brief_summary>
	<brief_title>Phase 3 Evaluation Re-Injection NX-1207 Treatment Benign Prostatic Hyperplasia ( BPH ) ( NX02-0022 )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Be male age 45 old . Sign inform consent form . Be good health . Received NX1207 previous complete study ( NX020020 ) receive NX1207 placebo concurrent U.S. study ( NX020017 NX020018 ) complete V10 ( 365 day ) visit . Have Prostate Gland Volume ≥ 25 mL ( 25 g ) . Surgery minimally invasive surgical therapy ( MIST ) treatment BPH first NX1207 injection Postvoid residual urine volume &gt; 200 mL Presence symptomatic median lobe prostate History use selfcatheterization urinary retention . Urinary retention previous 12 month . Prostatitis Urinary tract infection past 12 month Prostate bladder cancer . ProstateSpecific Antigen ( PSA ) ≥ 10 ng/mL Poorly control diabetes History evidence illness condition may interfere study endanger subject Participation study investigational drug ( NX1207 ) investigational device within previous 90 day Use specific prescribed medication may interfere study endanger subject</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Lower urinary tract symptom</keyword>
	<keyword>LUTS</keyword>
	<keyword>LUTS secondary BPH</keyword>
	<keyword>LUTS/BPH</keyword>
	<keyword>Benign prostatic obstruction ( BPO )</keyword>
	<keyword>BPO</keyword>
	<keyword>Bladder outlet obstruction</keyword>
	<keyword>BOO</keyword>
</DOC>